GMDA News and Press, Gamida Cell Ltd. From 03/09/21

Gamida ([[GMDA]] +4.7%) Q4 net loss for 2020 was $72.7M, compared to a net loss of $34.4M in 2019.GAAP EPS of -$1.66 misses consensus by $0.35.R&D expenses in 2020 were $41.4M, compared to $31.5M in 2019.As of December 31, 2020, had total cash and cash equivalents of $127.2 mill...

Gamida Cell (GMDA): FY GAAP EPS of -$1.66 misses by $0.35.Cash and cash equivalents of $127.2M.FY 2021 guidance: Cash used for ongoing operating activities in 2021 to range from $100M-120M.Press Release For further details see: Gamida Cell EPS misses by $0.35; outlook

– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021- — Omidubicel commercial preparation un...

GMDA addressed its cash issues, but its approval got a little delayed. That was because the FDA raised manufacturing concerns. The company seems confident in its ability to address those. For further details see: Gamida: Catalysts Ahead, Looks Interesting

We are circling back on Gamida Cell.  The stock has had a roller coaster ride since we last highlighted it in October. The company has recently addressed its funding needs. We update our investment thesis on this small cell therapy concern to account for recent news below. ...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in March: H.C. Wainwright Global Life Sciences Conferenc...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 9, 2021, at 8:30 a.m. ET to review its full year 2020 ...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that results from the Phase 3 clinical trial of omidubicel will be presented in an oral session at the Presidential Symposium of the 4...

These days, the real economy and the stock market seem to be in stark contrast to one another. While the annual U.S. real gross domestic product (GDP) growth rate has improved since the lows reported in June 2020, it's still far from from positive territory. Yet, the stock market is not ref...

Gamida Cell (GMDA) sold its $75M of 5.875% exchangeable senior notes due in 2026 to certain funds managed by Highbridge Capital Management.Proceeds along with proceeds of earlier sale of $75M ordinary shares in December 2020 are expected to provide Gamida Cell with sufficient liquidity to fun...